SAB Bio Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
SAB Bio announced positive topline data from a Phase 1 trial of SAB-142, a human anti-thymocyte immunoglobulin being developed...
Jon Napitupulu
Positive Topline Results in 5-MeO-DMT Study for Alcohol Use Disorder
Atai Life Sciences announced positive topline results from a Phase 2a study of BPL-003, a synthetic intranasal 5-MeO-DMT formulation,...
Oncomatryx Secures €25M to Advance OMTX705 Clinical Trials
Oncomatryx, a biopharmaceutical company developing antibody-drug conjugates (ADCs), secured €25 million to advance clinical trials of OMTX705, a first-in-class...
Lerodalcibep Shows Promise in HoFH Phase 3 Study
LIB Therapeutics‘ Phase 3 LIBerate-HoFH study results for lerodalcibep, a novel PCSK9 inhibitor, in patients with homozygous familial hypercholesterolemia...
Pediatric Erydex Safety in Ataxia-Telangiectasia: Long-Term Study Results
Quince Therapeutics announced the publication of long-term safety data from Ataxia-Telangiectasia (A-T) patients treated with EryDex for at least...
hVIVO and ILIAD Sign LOI for Pivotal Phase 3 Trial of BPZE1 Pertussis Vaccine
ILiAD Biotechnologies and hVIVO will collaborate on a Phase 3 human challenge trial for ILiAD’s next-generation intranasal pertussis vaccine,...
RenovoRx ASCO GI 2025: Promising Pharmacokinetic Data
RenovoRx announced promising pharmacokinetic data from a sub-study of its ongoing Phase III TIGeR-PaC clinical trial, investigating its Trans-Arterial...
FDA Grants Cartesian Special Protocol for Phase 3 Trial in Myasthenia Gravis
Cartesian Therapeutics (NASDAQ: RNAC) received FDA approval under the Special Protocol Assessment (SPA) process for the Phase 3 AURORA...
Adagene Announces Updated Data From Phase 1b/2 Study of Muza in Colorectal Cancer at ASCO GI
Adagene Inc. announced positive updated clinical data for ADG126 (muzastotug), an anti-CTLA-4 SAFEbody® drug, combined with pembrolizumab in a...
Ocugen’s OCU500 Inhaled COVID-19 Vaccine Enters Phase 1 Trial
Ocugen has received FDA approval to begin a Phase 1 clinical trial for OCU500, an inhaled and nasal spray...